Zoetis (NYSE:ZTS) Rating Reiterated by William Blair

Zoetis (NYSE:ZTSGet Rating)‘s stock had its “outperform” rating restated by equities research analysts at William Blair in a research report issued to clients and investors on Friday, PriceTargets.com reports. William Blair also issued estimates for Zoetis’ Q3 2022 earnings at $1.23 EPS, Q4 2022 earnings at $1.27 EPS, FY2022 earnings at $5.02 EPS, Q1 2023 earnings at $1.40 EPS and Q4 2023 earnings at $1.38 EPS.

A number of other research analysts also recently weighed in on the company. Piper Sandler began coverage on Zoetis in a research note on Monday, July 11th. They issued an “overweight” rating and a $205.00 price target on the stock. Stifel Nicolaus cut their price target on Zoetis from $275.00 to $225.00 and set a “buy” rating on the stock in a research note on Friday, June 24th. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, April 26th. Finally, The Goldman Sachs Group dropped their price objective on Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a research note on Thursday, July 21st. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $224.88.

Zoetis Stock Up 0.2 %

Shares of ZTS opened at $174.61 on Friday. The firm has a market capitalization of $82.18 billion, a price-to-earnings ratio of 40.05, a PEG ratio of 3.06 and a beta of 0.73. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.58 and a current ratio of 2.25. The business’s fifty day moving average price is $171.80 and its two-hundred day moving average price is $181.35. Zoetis has a 52 week low of $154.18 and a 52 week high of $249.27.

Zoetis (NYSE:ZTSGet Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported $1.20 earnings per share for the quarter, missing analysts’ consensus estimates of $1.22 by ($0.02). The company had revenue of $2.10 billion during the quarter, compared to analyst estimates of $2.03 billion. Zoetis had a net margin of 26.27% and a return on equity of 49.62%. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period last year, the company earned $1.19 EPS. On average, analysts predict that Zoetis will post 5.04 earnings per share for the current year.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 2,167 shares of the stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $180.26, for a total transaction of $390,623.42. Following the completion of the transaction, the executive vice president now owns 23,687 shares in the company, valued at approximately $4,269,818.62. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Kristin C. Peck sold 9,689 shares of the firm’s stock in a transaction dated Thursday, July 21st. The stock was sold at an average price of $180.00, for a total value of $1,744,020.00. Following the completion of the transaction, the chief executive officer now owns 39,743 shares in the company, valued at approximately $7,153,740. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Roxanne Lagano sold 2,167 shares of the firm’s stock in a transaction dated Friday, July 22nd. The shares were sold at an average price of $180.26, for a total value of $390,623.42. Following the completion of the transaction, the executive vice president now owns 23,687 shares of the company’s stock, valued at approximately $4,269,818.62. The disclosure for this sale can be found here. In the last 90 days, insiders sold 18,356 shares of company stock worth $3,250,158. Corporate insiders own 0.12% of the company’s stock.

Hedge Funds Weigh In On Zoetis

A number of hedge funds and other institutional investors have recently bought and sold shares of ZTS. American National Bank grew its holdings in Zoetis by 469.2% during the second quarter. American National Bank now owns 148 shares of the company’s stock worth $25,000 after purchasing an additional 122 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC lifted its position in Zoetis by 430.8% during the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock worth $26,000 after acquiring an additional 112 shares during the last quarter. Worth Asset Management LLC acquired a new stake in Zoetis during the first quarter worth approximately $26,000. Financial Management Professionals Inc. lifted its position in Zoetis by 117.4% during the first quarter. Financial Management Professionals Inc. now owns 150 shares of the company’s stock worth $28,000 after acquiring an additional 81 shares during the last quarter. Finally, Aquire Wealth Advisors LLC acquired a new stake in Zoetis during the fourth quarter worth approximately $32,000. Institutional investors own 90.73% of the company’s stock.

About Zoetis

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More

Analyst Recommendations for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.